Physician profile
Russell Harada
NPI 1730143884
$3,869.79
in general payments reported to CMS, 2019-2025
16 companies · $45.45 in 2025
The $45.45 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $333 · 2021: $2,939 · 2022: $85.87 · 2024: $72.27 · 2025: $45.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,558.96 | 2020-2024 | Oasis, Grafix Pl |
| Bard Peripheral Vascular, INC. | $441.53 | 2019-2021 | |
| Abbvie INC. | $171.30 | 2021-2024 | |
| Boston Scientific Corporation | $125.39 | 2021 | |
| Abbott Laboratories | $121.74 | 2020 | |
| Medtronic Vascular, INC. | $109.06 | 2019-2020 | |
| Allergan, INC. | $86.85 | 2019-2020 | |
| Mimedx Group, INC. | $47.13 | 2024-2025 | |
| Zimmer Biomet Holdings, INC. | $36.93 | 2021 | |
| Medtronic, INC. | $34.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $30.47 | 2022 | |
| Penumbra, INC. | $29.28 | 2022 | |
| Cardiovascular Systems INC. | $23.72 | 2019 | |
| Stryker Corporation | $23.42 | 2025 | Artix Mt |
| Artivion, INC. | $15.10 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Harada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.